BorderControl
Financiado
Regaining control of cancer at biological borders
During dissemination, cancer cells must face and overcome several physiological borders, including the immediate stroma for local invasion and the endothelium for long-distance metastasis. At these critical junctures, cell plastic...
During dissemination, cancer cells must face and overcome several physiological borders, including the immediate stroma for local invasion and the endothelium for long-distance metastasis. At these critical junctures, cell plasticity between epithelial (E) and mesenchymal (M) states could determine metastasis potential. Based on our preliminary data, ideally-positioned cues emanating from the normal stroma contain the tumour in situ. Once this first border is breached, rare cancer cell-endothelial interactions trigger further dissemination through the vascular border. Moreover, cancer cell plasticity is vital throughout this process, enabling optimal response to distinct border microenvironments. In BorderControl, we will build on our cutting-edge cell biology expertise and close collaboration with clinicians to define the molecular signals underlying these border “crossings” and gain unprecedented information on how cancer cells overwhelm these natural defences. Starting with patient tissues, we will spatially profile the tumour-stroma border to identify receptor-ligand pairs that regulate invasion. We will use microfluidics to image, catch and profile cancer cell crossings at endothelial hotspots and determine key molecular regulators of the process in endothelial and cancer cells. Building on our novel discovery of endosomally regulated E-M cell states, we will test how E-M transitions impact border-breaching potential. These novel concepts will be investigated with interdisciplinary methods (scRNAseq, synthetic biology, colour barcoded HTS) and our new technologies (dynamically tuneable multicell-type migration and invasion imaging platforms) to determine the specific interactions/mechanisms regulating border crossings. Finally, we will take the molecular level discoveries from the cancer-limiting borders back to the patients, assessing clinical relevance using designer TMAs, and expect to uncover novel biomarkers and therapeutically actionable targets.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2024-09-01
Fecha Fin: 2029-08-31
Fecha Fin: 2029-08-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2023-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
TURUN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5